Abstract
Recombinant fusion proteins are an expanding, important class of novel therapeutic agents. The designs of these constructs typically involve a cell-targeting motif genetically fused to a highly toxic class of enzymes capable of ruthlessly attacking critical cellular machinery once delivered successfully to the cytoplasm of the target cell. Initial development of this class of constructs typically contained recombinant growth factors or single-chain antibodies as the celltargeting motif fused to highly cytotoxic plant or bacterial toxins. This review describes second-generation molecules composed of cell-targeting molecules fused to highly cytotoxic human enzymes capable of generating intense apoptotic response once delivered to the cytoplasm. The human serine protease granzyme B has been shown to be extremely effective as a cytotoxic molecule when incorporated into numerous cell-targeting constructs. The biological activity of GrBcontaining constructs rivals that of plant or bacterial toxins and appears to represent a new generation and class of completely human proteins with unique biological activities.
Keywords: Fusion proteins, granzyme B, immunotoxins, serine protease, gp240, VEGF, serpins, H22
Current Pharmaceutical Design
Title: Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Volume: 15 Issue: 23
Author(s): M. G. Rosenblum and S. Barth
Affiliation:
Keywords: Fusion proteins, granzyme B, immunotoxins, serine protease, gp240, VEGF, serpins, H22
Abstract: Recombinant fusion proteins are an expanding, important class of novel therapeutic agents. The designs of these constructs typically involve a cell-targeting motif genetically fused to a highly toxic class of enzymes capable of ruthlessly attacking critical cellular machinery once delivered successfully to the cytoplasm of the target cell. Initial development of this class of constructs typically contained recombinant growth factors or single-chain antibodies as the celltargeting motif fused to highly cytotoxic plant or bacterial toxins. This review describes second-generation molecules composed of cell-targeting molecules fused to highly cytotoxic human enzymes capable of generating intense apoptotic response once delivered to the cytoplasm. The human serine protease granzyme B has been shown to be extremely effective as a cytotoxic molecule when incorporated into numerous cell-targeting constructs. The biological activity of GrBcontaining constructs rivals that of plant or bacterial toxins and appears to represent a new generation and class of completely human proteins with unique biological activities.
Export Options
About this article
Cite this article as:
Rosenblum G. M. and Barth S., Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions, Current Pharmaceutical Design 2009; 15 (23) . https://dx.doi.org/10.2174/138161209788923958
DOI https://dx.doi.org/10.2174/138161209788923958 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets Automated Electrophysiology in Drug Discovery
Current Pharmaceutical Design Industrial Chemicals and Acute Lung injury with a Focus on Exposure Scenarios
Current Respiratory Medicine Reviews Targeting Cardiomyocyte Ca<sup>2+</sup> Homeostasis in Heart Failure
Current Pharmaceutical Design Appraisal of AβPP Transgenic Mice as Models for Alzheimers Disease Amyloid Cascade
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets L-PRP/L-PRF in Esthetic Plastic Surgery, Regenerative Medicine of the Skin and Chronic Wounds
Current Pharmaceutical Biotechnology Optimising the Use of Non-Invasive Ventilation in the Intensive Care Setting
Current Respiratory Medicine Reviews Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Clinical Proteomics in Cancer Research
Current Proteomics Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases
Current Drug Targets Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Regenerative Therapies for Improving Myocardial Perfusion in Patients with Cardiovascular Disease: Failure to Meet Expectations but Optimism for the Future
Current Vascular Pharmacology